Home › Mantle Cell Lymphoma › California

Pag-aaral pangklinika para sa Mantle Cell Lymphoma sa California

31 pag-aaral para sa Mantle Cell Lymphoma ang naghahanap ng mga kalahok sa mga site sa California.

Mga Lungsod sa California

Opisyal na teksto ng pag-aaral (English)

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

City of Hope Comprehensive Cancer Center, Duarte

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT07003295

BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

City of Hope Medical Center, Duarte
Stanford University, Stanford

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Nob 10, 2026 · NCT05370430

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

City of Hope, Duarte

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT07101328

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

Tower Cancer Research Foundation, Beverly Hills
Cedars-Sinai Medical Center, Los Angeles

Nagre-recruitPhase 3

Edad 60 pataas · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT05976763

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

City of Hope Medical Center, Duarte

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT06054776

A Study of ARC-02 in B-cell NHL

Start Cala, Los Angeles

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Nob 2, 2026 · NCT07691606

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

Ucsf Fresno, Fresno
Kaiser Permanente Southern California, Irvine

Nagre-recruitPhase 3

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 29, 2026 · NCT06742996

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

City of Hope Medical Center, Duarte

Nagre-recruitPhase 1/2

Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Okt 26, 2026 · NCT05861050

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

City of Hope, Duarte
Valkyrie Clinical Trials, Los Angeles

Nagre-recruitPhase 1/2

Edad 13 hanggang 90 · Lahat ng kasarian · Na-update Okt 26, 2026 · NCT06533579

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

University of California, San Francisco, San Francisco

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 26, 2026 · NCT04545762

Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

City of Hope Medical Center, Duarte

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 22, 2026 · NCT07578077

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

START Los Angele, Los Angeles

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 15, 2026 · NCT07424833

Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

City of Hope Medical Center, Duarte

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 14, 2026 · NCT06675123

Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

City of Hope Medical center, Duarte

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 14, 2026 · NCT03523975

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

University of California San Diego (Ucsd) Moores Cancer Center, La Jolla
Stanford Medicine, Palo Alto
UCLA Santa Monica Cancer Care, Santa Monica

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT05006716

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

University of California, Davis, Davis
University of California, Los Angeles, Los Angeles
University of California, San Diego, San Diego
at 1 pa

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT06252675

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Research Site, La Jolla

Nagre-recruitPhase 1/2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT06542250

Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL

Stanford Cancer Center, Stanford

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT06553872

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

Stanford University, Palo Alto

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Ago 12, 2026 · NCT06340737

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

Cedars-Sinai Medical Center, Los Angeles

Nagre-recruitPhase 1

Edad 18 hanggang 85 · Lahat ng kasarian · Na-update Ago 10, 2026 · NCT05887167

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

City of Hope, Duarte

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Hul 24, 2026 · NCT07121946

DALY II USA/ MB-CART2019.1 for DLBCL

UC San Diego Health, La Jolla
Stanford University, Stanford

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Hul 13, 2026 · NCT04792489

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

City of Hope, Duarte
University of California, San Francisco, San Francisco

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Hul 2, 2026 · NCT05131022

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

City of Hope Medical Center, Duarte

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Abr 20, 2026 · NCT06859008

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

City of Hope, Duarte
Los Angeles Cancer Network, Los Angeles
UCLA Medical Center of Hematology/Oncology, Los Angeles
at 1 pa

Nagre-recruitPhase 1/2

Edad 12 hanggang 95 · Lahat ng kasarian · Na-update Abr 15, 2026 · NCT04329728

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

City of Hope, Duarte

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Mar 20, 2026 · NCT04830137

Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma

City of Hope Medical Center, Duarte
City of Hope at Irvine Lennar, Irvine

Nagre-recruitPhase 2

Edad 18 pataas · Lahat ng kasarian · Na-update Mar 13, 2026 · NCT06572618

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

City of Hope Medical Center, Duarte

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Peb 23, 2026 · NCT05432635

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

UC Irvine Health, Orange

Nagre-recruitPhase 1

Edad 18 pataas · Lahat ng kasarian · Na-update Dis 10, 2025 · NCT05602363

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio SYNERGY-AI site, Duarte
Massive Bio SYNERGY-AI site, Irvine
Massive Bio SYNERGY-AI site, La Jolla
at 3 pa

Nagre-recruitObservasyonal na pag-aaral

Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774

Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy

Stanford Cancer Center, Palo Alto

Nagre-recruitObservasyonal na pag-aaral

Edad 18 pataas · Lahat ng kasarian · Na-update Ago 22, 2024 · NCT05255354

Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.